Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
Date:3/8/2011

SAN DIEGO, March 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2010 financial results before the NASDAQ Global Select Market opens on Friday, March 11, 2011. That same morning, Jack Lief, Arena's President and Chief Executive Officer, will host a conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2010 and to provide a business and financial update.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Fourth Quarter and Full Year 2010 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is lorcaserin, which is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
2. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
4. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
6. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
7. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
8. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
9. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
10. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
11. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
Breaking Medicine Technology:
(Date:7/26/2017)... CA 92660 (PRWEB) , ... July 26, ... ... Loss Prevention for on-premises, off and in the cloud ; today announced the ... and scientific algorithms within a simple to use control console for Data Discovery, ...
(Date:7/26/2017)... ... 26, 2017 , ... “We are thrilled to be partnering with Six Month ... an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients the ... bring more Six Month Smiles patients to their providers.” , Each month, over 25,000 ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... IDC-Eating ... Medical Director for the treatment program located in Royal Oak, Michigan. IDC, ... investors who are focused on providing the highest standards in the field of eating ...
(Date:7/26/2017)... Monroe, LA (PRWEB) , ... July 26, 2017 , ... ... - 2:00 p.m. at Charles Johnson Park at 3313 Bernstein Park Drive in Monroe ... Amnesty Rally is to help reduce gun violence throughout Monroe. Citizens can ...
(Date:7/26/2017)... Springs, FL (PRWEB) , ... July 26, 2017 ... ... the nation’s leading innovative specialty pharmacies, has released an updated version of the ... the latest guidelines for treating chronic hepatitis C virus (HCV) infection. All of ...
Breaking Medicine News(10 mins):